Status:
WITHDRAWN
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
Lead Sponsor:
University of North Carolina, Chapel Hill
Conditions:
Pituitary Tumor
Blood Loss
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compare...
Eligibility Criteria
Inclusion
- Undergoing endoscopic pituitary surgery at UNC
Exclusion
- Clival invasion
- Giant pituitary tumor (\>4 cm)
- Revision pituitary surgery
- Prior sinus surgery
- Lund McKay score \> 3
- Active thromboembolic disease
- Coagulopathy
- Concomitant pro-thrombotic medications
- Concomitant use of anti-coagulants or anti-platelet agents
- Subarachnoid hemorrhage
- History of severe hypersensitivity to Tranexamic Acid
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04863339
Start Date
March 1 2022
End Date
April 1 2022
Last Update
April 5 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.